Citations

Clear

511 citation(s) found for "Seth, N".

Treatment of Multiple Myeloma: ASCO Living Guideline, Version 2026.1.1
Banerjee, Rahul , Cheung, Matthew C. , Derman, Benjamin, Messersmith, Hans , Bhella, Sita, Chmielewski, Cynthia, Ebraheem, Mohammad, Kennedy, C. Todd , Kumar, Shaji , Langerak, Alan, Mian, Hira , Seth, Rahul, Subramanian, Latha, Wildes, Tanya M., Zanwar, Saurabh , Zhuo, Ying, Derman, Benjamin A , Al Hadidi, Samer , Ebraheem, Mohammad S , Kennedy, C Todd , Kumar, Shaji K , Lipe, Brea , Mian, Hira , Riva, Eloisa , Usmani, Saad , Wildes, Tanya , Zanwar, Saurabh S , Hicks, Lisa K. , Messersmith, Hans , Banerjee, Rahul , Derman, Benjamin A. , Chmielewski, Cynthia, Langerak, Alan, Seth, Rahul, Usmani, Saad Z. , Wildes, Tanya M.

Mayo Clinic

Journal of Clinical Oncology | May 20, 2026 | Volume: 44 | Issue: 22 | Pages: No page available

10.1200/jco-26-01139 | PMID 42160714 Get It

This guideline has been updated. This ASCO Living Guideline is reviewed on an eight-week cycle. Please see the online dynamic version for the latest updates. Living guidelines are developed for selected topic areas with rapidly evolving evidence that drives frequent change in recommended clinical practice. Living guidelines are updated on a regular schedule by a standing expert panel that systematically reviews the health literature on a continuous basis, as described in the ASCO Guidelines Methodology Manual . ASCO Living Guidelines follow the ASCO Conflict of Interest Policy Implementation for Clinical Practice Guidelines . Living Guidelines and updates are not intended to substitute for independent professional judgment of the treating clinician and do not account for individual variation among patients. See appendix for disclaimers and other important information ( Appendix 1 and Appendix 2 ). Updates are published regularly and can be found on the ASCO Publications website .
Generalizable spinal cord multiple sclerosis lesion segmentation across MRI contrasts, protocols, and centers
Benveniste, Pierre‐Louis , Létourneau‐Guillon, Laurent , Araújo, David , Fetco, Dumitru , Hori, Masaaki , Kamiya, Kouhei , Messina, Steven, Audoin, Bertrand , Blezek, Daniel, Brisset, Jean‐Christophe , Charlson, Erik, Chen, Michelle , Demortière, Sarah , Edan, Gilles , Filippi, M, Kerbrat, Anne , Kirschke, J, Labauge, Pierre, Liu, Yaou, Mainero, Caterina , Medina, Nilser Laines , Reich, Daniel S. , Shepherd, Timothy M. , Smith, Seth A. , Talbott, Jason, Tauhid, Shahamat , Treaba, Constantina A. , Cohen-Adad, Julien, Fetco, Dumitru , Hori, Masaaki , Audoin, Bertrand , Bakshi, Rohit , Bannier, Elise , Blezek, Daniel , Brisset, Jean-Christophe , Callot, Virginie , Chen, Michelle , Ciccarelli, Olga , Edan, Gilles , Filippi, Massimo , Granberg, Tobias , Granziera, Cristina , Hemond, Christopher C , Keegan, B Mark , Kerbrat, Anne , Kirschke, Jan , Kollind, Shannon H , Lee, Lisa Eunyoung , McGinnis, Julian , Laines Medina, Nilser , Mühlau, Mark , Nair, Govind , O'Grady, Kristin P , Oh, Jiwon , Ouellette, Russell , Reich, Daniel S , Rocca, Maria A , Smith, Seth A , Stawiarz, Leszek , Tam, Roger , Traboulsee, Anthony , Treaba, Constantina Andrada , Valsasina, Paola , Yiannakas, Marios , Cohen-Adad, Julien , Guillon, Laurent Letourneau , Chougar, Lydia , Messina, Steven A. , Tsagkas, Charidimos , Blezek, Daniel J. , Ciccarelli, Olga , Filippi, Massimo , Keegan, B. Mark , Labauge, Pierre , Lee, Lisa Eunyoung , Nair, Govind , O’Grady, Kristin P. , Prat, Alexandre , Rocca, Maria A. , Talbott, Jason F. , Tam, Roger , Lombaert, Hervé

Mayo Clinic

Multiple Sclerosis Journal | April 24, 2026 | Volume: 32 | Issue: 6 | Pages: 598-613

10.1177/13524585261427333 | PMID 42028790 Get It

Background/Objectives: Characterizing spinal cord multiple sclerosis (MS) lesions in MRI is critical for diagnosis, monitoring, and treatment evaluation. However, current automated approaches for lesion detection and segmentation are typically designed for specific MRI contrasts or acquisition sites, limiting their generalizability in real-world clinical settings where imaging protocols vary widely. This work proposes a robust multi-site, multi-contrast segmentation framework for spinal cord lesions. Methods: The segmentation model was trained and evaluated on a large-scale dataset comprising 4428 annotated images from 1849 persons with MS across 23 imaging centers, encompassing six MRI contrasts (T1w, T2w, T2*w, PSIR, STIR, and UNIT1) acquired at 1.5 tesla (T), 3 T, and 7 T. Results: Likert-type assessment performed by neuroradiologist ratings demonstrated superior generalization of the model compared to existing contrast-specific pipelines ( p < 0.01). Additional experiments evaluated robustness across spinal levels, acquisition resolutions, binarization thresholds, and quantitative evaluation on external labeled datasets. Conclusions: The proposed model can achieve accurate and reliable spinal cord MS lesion segmentation across heterogeneous MRI data, addressing a key barrier to clinical translation. The model is available in the Spinal Cord Toolbox v7.2 and higher. Code repository: https://github.com/ivadomed/seg-sc-ms-lesion-multicontrast
Abstract CT075: Lack of CTPS2 expression exposes synthetic lethal vulnerability to selective CTPS1 inhibition: A phase 1 dose escalation study of dencatistat (STP938) with safety expansion in biomarker selected cohorts
Graham, Donna M. , Sommerhalder, David , Orr, Douglas, Miller, Rowan, Makani, Neeharika, O’Malley, DM, Winer, Ira, Beer, Philip, Smith, Karen, Higgins, Maureen , Hawse, John R. , Wang, X, Weroha, Saravut J., Massard, Christophe , Makani, Neeharika Srivastava, Winer, Ira Seth , Beer, Philip , Higgins, Maureen, Roxburgh, Patricia

Mayo Clinic

Cancer Research | April 17, 2026 | Volume: 86 | Issue: 8_Supplement | Pages: CT075-CT075

10.1158/1538-7445.am2026-ct075 Get It

Abstract Background: Pyrimidine synthesis is a therapeutic vulnerability in cancer but inhibition results in toxicity to normal cells. Differential targeting of CTP synthase 1 (CTPS1), sparing the CTPS2 isoenzyme, is a therapeutic strategy in lymphoid cancers, supported by human genetic studies, that can potentially avoid toxicity; however, CTPS2 activity may compensate in epithelial tumours. Loss of CTPS2 protein expression characterises 25% of solid tumours and is predicted to expose a synthetic lethal vulnerability to CTPS1 inhibition. Dencatistat (STP938) is a first in class oral CTPS1 inhibitor showing &gt;1,300-fold selectivity over CTPS2. In preclinical studies, CTPS2 expression was confirmed as a key modulator of response to CTPS1 inhibition, and dencatistat induced tumour regression in an in vivo model of CTPS2 negative ovarian cancer. Study design: The study comprises a standard 3+3 phase 1a dose escalation design, in which intra-patient dose escalation is encouraged, followed by a phase 1b safety expansion. The dose escalation study is recruiting participants with high grade advanced tumours who have exhausted standard of care therapy (excluding haematological cancers, salivary gland tumours and low grade tumours of any tissue). In addition, participants with high grade serous ovarian cancer whose tumours lack expression of CTPS2 (per central laboratory testing by immunohistochemistry) are eligible for backfill into cleared cohorts during dose escalation. The recommended phase 2 dose (RP2D) will be nominated based on safety, tolerability, target engagement and early signs of clinical efficacy. The phase 1b safety expansion study will recruit participants with CTPS2 negative ovarian, lung or endometrial cancer who will receive treatment at the RP2D. Standard inclusion criteria apply; patients with ECOG performance score &gt;2 (&gt;1 for phase 1a in France) or active/symptomatic CNS metastases are not eligible. The primary objectives of the study are to evaluate the safety and tolerability of single agent dencatistat and to determine the RP2D for further development. Secondary objectives comprise evaluation of pharmacokinetic properties and preliminary clinical activity. Exploratory endpoints include evaluation of target engagement, molecular features associated with response, and determination of drug metabolites. The study opened to enrolment in the UK, France and USA in September 2024 and is currently in dose escalation (NCT06297525). The phase 1b study is expected to commence mid-2026 and will include additional centres in Spain. Citation Format: Donna M. Graham, David Sommerhalder, Douglas Orr, Rowan Miller, Neeharika Makani, David O'Malley, Ira Winer, Philip A. Beer, Karen Smith, Maureen Higgins, John R. Hawse, Xiyin Wang, Saravut J. Weroha, Christophe Massard, Patricia Roxburgh. Lack of CTPS2 expression exposes synthetic lethal vulnerability to selective CTPS1 inhibition: A phase 1 dose escalation study of dencatistat (STP938) with safety expansion in biomarker selected cohorts [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 2 (Late-Breaking, Clinical Trial, and Invited Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(8_Suppl):Abstract nr CT075.
Bronchial Mucosal Abnormalities in Idiopathic Subglottic Stenosis
Ring, Sydney , Bowen, Andrew J. , Griffin, Tessa C. , Ferguson, J. Scott , Dailey, Seth H. , Bowen, Andrew Jay , Griffin, Tessa

Mayo Clinic

The Laryngoscope | April 12, 2026 | Volume: 136 | Issue: 8 | Pages: 3527-3533

10.1002/lary.70543 | PMID 41966683 Get It

ABSTRACT Objectives Investigate synchronous lower airway findings during bronchoscopy in idiopathic subglottic stenosis (iSGS). Methods Retrospective analysis of bronchoscopic images from adult iSGS patients (January 2018–June 2021). Images were reviewed for pits, depressions, nodules, and striations distal to the cricotracheal junction. Results Forty‐eight female patients; mean age 56 years. Comorbidities: gastroesophageal reflux 34%, hypertension 34%, diabetes mellitus 25%. All patients had pits and depressions; striations in 48/48, with both longitudinal and transverse in 32/48 (66.7%), transverse only in 13/48 (27.1%), and longitudinal only in 3/48 (6.3%). Spirometry available in 32; 60% showed normal or mild–moderate fixed obstruction. Four patients had FEV 1 /FVC < 0.7; two had asthma, one COPD, and one no obstructive diagnosis; none were smokers. Conclusion Bronchial mucosal abnormalities are prevalent in iSGS and may indicate distal airway involvement. Routine flexible bronchoscopy should be considered during evaluation and surveillance. Level of Evidence 4.
Clinical, Genetic, and Pathologic Variability in Myelodysplastic Syndromes and Precursor Conditions Across Race, Ethnicity, and Sex
Colin‐Leitzinger, Christelle, Tang, Yi-Han , Sherman, Seth, Zhang, Ling, Walker, Mary Ellen, Painter, Jeffrey S. , Abel, Gregory A., Baghdadi, Tareq Al, Deeg, H. Joachim, Foran, James M., Gore, Steven D., Harrington, Alexandra M., Kroft, Steven H. , Liu, Jane Jijun, Saber, Wael, Virani, Shamsuddin, Bejar, Rafael, Padron, Eric , Komrokji, Rami, DeZern, Amy E., Sekeres, Mikkael A., Colin, Christelle , Foran, James M , Gillis, Nancy , Otterstatter, Michael , Zhang, Ling , Moscinski, Lynn C. , Walker, Mary E. , Abel, Gregory A. , Deeg, H. Joachim , Foran, James M. , Gore, Steven D. , Saber, Wael , Bejar, Rafael , Lindsley, R Coleman , Walter, Matthew J , Komrokji, Rami, Dezern, Amy Elizabeth , Sekeres, Mikkael A.

Mayo Clinic

American Journal of Hematology | March 30, 2026 | Volume: 101 | Issue: 6 | Pages: 1407-1420

10.1002/ajh.70279 | PMID 41906220 Get It

ABSTRACT The epidemiology of myelodysplastic syndromes/neoplasms (MDS) is challenging to define due to inconsistent reporting, complex diagnostic procedures, and evolving diagnostic criteria. Using the National MDS Natural History Study—a prospective cohort with centrally adjudicated histopathology and genetic variant review—we characterized the landscape of MDS across the United States and identified differences across demographics. Among 2115 participants, 64% (1346) had an MDS spectrum condition, including MDS (24%), MDS/myeloproliferative neoplasm (5%) and precursor conditions—clonal cytopenia of undetermined significance (22%) and idiopathic cytopenia/dysplasia of undetermined significance (13%). The median age was 74 years, and participants were predominantly male (66%), White (91%), and Non‐Hispanic (92%). Myeloid‐associated variants were detected in 68% of participants, most commonly in TET2, DNMT3A, ASXL1, SF3B1, and SRSF2 . Black, compared to White, participants were younger at diagnosis (69 vs. 74 years, p = 0.01), had equal or increased prevalence of higher‐risk MDS, lower hemoglobin, and higher peripheral blood blasts, yet were less likely to receive MDS‐directed therapy (14% vs. 42%, p = 0.008). Black and Hispanic participants had fewer detectable gene mutations than White participants. Females had lower variant allele frequencies and fewer RNA splicing gene mutations than males. After multivariable adjustment, TP53 mutations, MDS diagnosis, and higher‐risk disease were associated with worse progression‐free and overall survival; age was also associated with overall survival. Black race trended toward improved progression‐free survival. These findings highlight the need for enhanced understanding of MDS pathogenesis across patient groups and refined prognostic tools to improve personalized management of MDS spectrum conditions. Trial Registration: ClinicalTrials.gov identifier: NCT02775383
Clinical Criteria for the Definition of Refractory Septic Shock: A Joint Delphi Consensus from the Society of Critical Care Medicine (SCCM) and European Society of Intensive Care Medicine (ESICM)
Myatra, Sheila Nainan , Dugar, Siddharth , Russell, Lene , Delamarre, Louis , Sharif, Sameer , Chew, Michelle S. , Gong, Michelle N. , Hernández, Glenn , Martín‐Loeches, Ignacio , Dünser, Martin W., Einav, Sharon , Hamzaoui, Olfa, Frazee, Erin N. , Busse, Laurence W. , Deutschman, Clifford S. , Holder, Andre L. , Nazer, Lama , Nunnally, Mark , Rincon, Teresa , Seymour, Christopher W. , Besen, Bruno Adler Maccagnan Pinheiro , Finfer, Simon , Machado, Flávia Ribeiro , Mer, Mervyn , Young, Paul J. , Khanna, Ashish , Dugar, Siddharth , Wieruszewski, Patrick M , Russell, Lene , Evans, Laura , Delamarre, Louis , Sharif, Sameer , Chew, Michelle S , Gong, Michelle Ng , Hernández, Glenn , Schorr, Christa , Lakbar, Ines , Smith, Susan E , Martin-Loeches, Ignacio , Annane, Djillali , Balik, Martin , Cecconi, Maurizio , De Backer, Daniel , Donadello, Katia , Einav, Sharon , Ferrer, Ricard , Juffermans, Nicole , Hamzaoui, Olfa , Landoni, Giovanni , Levy, Bruno , McKenzie, Cathrine , Monnet, Xavier , Ostermann, Marlies , Spies, Claudia D , Singer, Mervyn , Theodorakopulou, Maria , Topeli, Arzu , Frazee, Erin N , Bauer, Seth R , Busse, Laurence W , Coopersmith, Craig M , Deutschman, Clifford , Holder, Andre L , Kamaleswaran, Rishikesan , Legrand, Matthieu , Martin, Greg S , Maves, Ryan C , Nazer, Lama , Nunnally, Mark E , Prescott, Hallie C , Rincon, Teresa , Sacha, Gretchen , Seymour, Chris W , Arabi, Yaseen M , Besen, Bruno Amp , Cavalcanti, Alexandre Biasi , Deane, Adam M , Finfer, Simon , Hammond, Naomi , Ibarra-Estrada, Miguel , Kattan, Eduardo , Kotani, Yuki , Machado, Flavia R , Ospina-Tascón, Gustavo A , Mer, Mervyn , Young, Paul J , Rochwerg, Bram , Khanna, Ashish K , Léone, Marc , Wieruszewski, Patrick M. , Smith, Susan , Backer, Daniel De , Dünser, Martin W. , Lévy, Bruno , McKenzie, Cathrine , Ostermann, Marlies , Spies, Claudia , Kamaleswaran, Rishikesan , Legrand, Matthieu , Martin, Greg S. , Maves, Ryan C. , Prescott, Hallie C. , Arabi, Yaseen M. , Deane, Adam M. , Hammond, Naomi

Mayo Clinic

Critical Care Medicine | March 24, 2026 | Volume: 54 | Issue: 5 | Pages: 1073-1091

10.1097/ccm.0000000000007124 | PMID 41873857 Get It

OBJECTIVE: A definition of refractory septic shock is necessary to guide diagnosis, management, prognostication, research, and future guidelines for this most severe form of the disease. We sought to achieve consensus on clinical criteria that would be used to define refractory septic shock. DESIGN: Review of literature, expert panel position statements, and Delphi rounds with an international expert group. SETTING: Consensus was defined as having at least 75% of panellists in agreement or disagreement on the three highest or lowest levels of a 7-point Likert scale or based on responses to single- or multiple-choice questions, respectively. SUBJECTS: A panel of multinational, multiprofessional and multidisciplinary critical care experts assembled by the Society of Critical Care Medicine and the European Society of Intensive Care Medicine (57 invitations and 56 participants). MEASUREMENTS AND MAIN RESULTS: A five-round Delphi process was conducted for consensus and stability. The steering committee proposed 34 statements, and five of them were rejected by panel experts after round 2. Among 29 statements selected from eight domains, consensus was reached for 13. The panel agreed on the need for a comprehensive consensus set of clinical criteria for refractory septic shock. Markers of organ dysfunction (75%, 2 rounds), tissue perfusion (91.1%, 2 rounds) including lactate (94.6%, 2 rounds) and capillary refill time (76.8%, 2 rounds), assessment of fluid-responsiveness after initial resuscitation (92.9%, 5 rounds), and use of vasoactive drugs at norepinephrine equivalents greater than 0.5 µg/kg/min (75.0%, 3 rounds), were selected as clinical criteria of refractory septic shock. The use of critical care ultrasound (CCUS) (92.9%, 3 rounds) was the single diagnostic modality that reached a consensus-based agreement. CONCLUSIONS: A consensus for 13 criteria to frame the definition of refractory septic shock was reached. Refractory septic shock is characterised by persistently elevated lactate concentrations and or prolonged capillary refill time in patients with septic shock who are fluid unresponsive, require a norepinephrine base equivalent dose greater than 0.5 micrograms per kilogram per minute, and undergo CCUS assessment when mixed shock is suspected.
ABC’S of AI: proposing a clinician’s framework for the interpretation of artificial intelligence studies
Murray, Brian, Bauer, Seth R., Gao, Yanjun, Frazee, Erin N. , Henry, Kelli , Blotske, Kaitlin , Murray, Brian , Bauer, Seth R , Sikora, Andrea

Mayo Clinic

Frontiers in Medicine | March 11, 2026 | Volume: 13 | Issue: No issue available | Pages: No page available

10.3389/fmed.2026.1787075 | PMID 41889498 Get It

Artificial intelligence (AI) and machine learning have emerged as transformative analytic methods capable of identifying patterns and proposing treatment strategies from complex, heterogeneous data generated in patient care settings. However, translating reports of AI tools into clinical decision-making requires careful interpretation and contextualization. Here, we present a structured framework (ABCDEFG framework) for clinicians to critically appraise studies reporting AI tools using a high-profile reinforcement learning analysis of vasopressin initiation in septic shock as a case example. We highlight key methodological strengths including adherence to reporting standards, alignment with clinical outcomes, and external validation. We also identify limitations related to causal inference, reward structure design, assumptions about state representation, and implementation readiness. Our framework emphasizes the importance of rigorous, clinically grounded critique before integrating AI tools into practice, and provides a roadmap for clinicians to assess the reliability and relevance of emerging AI-based decision support.
SWOG 2427: Single arm phase II study of bladder preservation with immunoradiotherapy after a clinically meaningful response to neoadjuvant therapy in patients with muscle invasive bladder cancer (BRIGHT).
Ballas, Leslie K., Callis, Samuel, Daneshmand, S., Tripathi, Abhishek, Hamstra, Daniel Allan, Yu, James B., Tyson, Mark D. , Meeks, Joshua J., McConkey, David James, Rose, Kyle M., Tawagi, Karine, Mittal, Kriti , Sachdev, S., Flaig, Thomas W. , Lerner, Seth P., Ballas, Leslie , Daneshmand, Siamak , Tripathi, Abhishek , Hamstra, Daniel A. , Mouw, Kent W. , Meeks, Joshua J. , McConkey, David J., Rose, Kyle M., Tawagi, Karine , Sachdev, Sean , Lerner, Seth P.

Mayo Clinic

Journal of Clinical Oncology | March 2, 2026 | Volume: 44 | Issue: 7_suppl | Pages: No page available

10.1200/jco.2026.44.7_suppl.tps913 Get It

TPS913 Background: A subset of patients with MIBC who receive neoadjuvant therapy (NAT) prior to radical cystectomy (RC) have a pathologic complete response (pCR) at the time of RC. With pCR rates of 22-42% in patients with MIBC following NAT (+/- ICI), whether a subset of patients with good clinical response to NAT can avoid RC is an important unanswered question, especially with the development of more active systemic therapies. HCRN 16-257 evaluated maintenance nivolumab in lieu of cystectomy in patients with MIBC who experienced clinical complete response (cCR) following neoadjuvant GC and nivolumab. The cCR rate was 48%, but 8/33 (24%) patients who elected bladder preservation subsequently underwent cystectomy for local disease recurrence. The RETAIN trial also evaluated omission of local therapy following neoadjuvant therapy with a 2-year bladder preservation rate in patients with ≤T1 disease following NAC of 54% (22/41). Of the 9/25 (36%) patients on that trial developed metastatic disease, 8/9 developed localized disease before metastasizing. These data illustrate the critical role that local therapy plays in patients with MIBC. For this reason, we believe that radiotherapy to the bladder combined with ICI will improve bladder intact event-free survival (BI-EFS). This trial also allows for patients to opt for bladder preservation based on a good clinical response to NAT. Methods: This is a single arm, phase 2 trial (NCT07061964) evaluating risk-adapted bladder preservation therapy for patients with MIBC following NAT. NAT consists of any NCCN guideline concordant therapy for MIBC. Patients with cT2-T4aN0M0 MIBC who complete NAT will be eligible if they have ≤T1 disease on post-NAT TURBT, confirmed by biopsies of prior tumor sites and systematic sampling (left/right lateral walls, dome, posterior wall, trigone). Patients will receive 55 Gray (Gy) in 20 fractions of radiotherapy (RT) to the bladder with 1 year of pembrolizumab. The primary objective is to evaluate whether 3-year BI-EFS is at least 70% in participants with < = T1 (without multifocal CIS) following NAT and RT with 1 year of pembrolizumab. Secondary objectives include local muscle invasive recurrence-free survival, metastasis-free survival (MFS), overall survival (OS), the rate of salvage cystectomy, and evaluation of the frequency and severity of toxicities in participants who receive RT and pembrolizumab. Plasma and urine will be banked for future correlative studies. S2427 was activated in September 2025 with an accrual goal of 111 patients. Clinical trial information: NCT07061964 .
SWOG S1602: A phase III randomized trial to evaluate BCG strain differences and priming with intradermal BCG before intravesical therapy for BCG-naïve high-grade non-muscle invasive bladder cancer (NCT #03091660).
Svatek, Robert S. , Tangen, Catherine, Meeks, Joshua J., Gilbert, Scott Michael, Lotan, Y., Tyson, Mark D. , Crispen, Paul L. , Delacroix, Scott Edward, Gills, Jessie, Daneshmand, S., Woods, Michael, Master, Viraj A., Mark, J. Ryan, Alva, Ajjai , Bangs, Rick , Nakagawa, Darrell , Plets, Melissa , Thompson, Ian Murchie, Lerner, Seth P., Meeks, Joshua J. , Gilbert, Scott M. , Delacroix, Scott Edward , Daneshmand, Siamak , Master, Viraj A. , Unger, Joseph M. , Thompson, Ian M. , Lerner, Seth P.

Mayo Clinic

Journal of Clinical Oncology | March 2, 2026 | Volume: 44 | Issue: 7_suppl | Pages: No page available

10.1200/jco.2026.44.7_suppl.lba629 Get It

LBA629 Background: Whether BCG strain influences clinical efficacy is unclear. BCG shortages and a reliance on a single strain may impact disease outcomes. Evidence also suggests that priming with intradermal (ID) BCG vaccination prior to intravesical (IVe) BCG enhances anti-tumor immunity and cancer clearance. Co-primary objectives address these issues. Methods: The trial design calls for 924 eligible patients with BCG naïve non-muscle invasive bladder cancer (NMIBC) (HG Ta/T1 +/- CIS or CIS alone) with negative purified protein derivative (PPD) to be randomized in a 1:1:1 ratio, to IVe TICE (Arm 1), IVe Tokyo-172 (Arm 2), or ID + IVe Tokyo-172 (Arm 3) BCG, stratifying on age group and clinical stage. IVe BCG included 6 weekly instillations (induction) and three weekly instillations (maintenance) at 3 and 6 months (mo), then every 6 mo for 3 years. Objective 1 tests whether Tokyo-172 BCG is non-inferior (NI) to TICE BCG, specifying a NI hazard ratio=1.34 (84% power). Objective 2 tests whether priming with ID prior to IVe Tokyo-172 is superior to IVe Tokyo-172 (HR=0.71, 83% power). The primary endpoint is high-grade recurrence-free survival (HG-RFS) censored at last cystoscopy, using a one-sided α=0.021 for each test. A Cox model adjusting for the stratification factors is used. Secondary endpoints include adverse events, 6-mo biopsy-proven complete response (CR) in patients with CIS +/- Ta, T1, duration of CR, PPD conversion and HG-RFS, progression-free survival (PFS) and quality of life. Max follow-up is 5 years. Results: 1000 (984 eligible) patients were enrolled from 2/17-12/20. Median (IQR) follow up is 4.6 (3.6, 5.0) yrs. Median age (range) is 70 yrs (26, 99), 17% are female, 9% are non-white, and 34% had CIS at entry. HG-RFS, CR, duration of CR at 4 yrs, and PFS were similar among arms (Table). PPD conversion occurred in 29% and was not correlated with HG-RFS. Gr 1-2 AE rate was similar (67%, 71%, and 67%) and Gr 3-4 (no Gr 5s) rate was 6%, 11%, and 14% for Arms 1,2, and 3, respectively. Conclusions: Tokyo-172 is non-inferior to TICE BCG in terms of HG RFS and CIS CR and is similar for PFS. Gr 3-4 AE rate is higher with Tokyo-172. Priming with Tokyo-172 BCG does not improve HG RFS. PPD conversion is not prognostic. Clinical trial information: NCT #03091660 . CIS Component N (eligible) 5-yr HG RFS HG RFSHR (95.8% CI) @ 5-yrPFS PFS HR(95% CI) @ CR %(95% CI) 4 yr CR duration Tice Ive 333 (330) 58% 79% 62%; 71/114(53%, 71%) 80% Tokyo Ive 332 (327) 64% *0.82(0.63, 1.08) 79% *0.99(0.70, 1.39) 60%; 66/110(50%, 69%) 83% Tokyo ID + Ive 335 (327) 63% **1.00(0.76, 1.33) 77% **1.07(0.76, 1.51) 63%; 69/109(54%, 72%) 80% 3 mo. PPD + conversionY vs. N 782 evaluable225 (29%)557 (71%) 69%67% ^HR=0.91(0.68, 1.22) * Tokyo-172 vs. Tice, ** Tokyo Priming vs. Tokyo no priming. ^conversion to PPD + vs. – @ adjusted for 2 strat factors (and arms for PPD model). PFS event = MIBC, metastasis, or death.